Author

Alejo Rodriguez-Vida

Observed name: A. Rodriguez-Vida

Institution: Hospital del Mar Research Institute

Observed institutions: Hospital Del Mar, Parc de Salut, Municipal Institute for Medical Research, Hospital del Mar Research Institute

ORCID: 0000-0002-2518-485X

Observed ORCID: 0000-0002-2518-485X

OpenAlex ID: A5023964082

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

2025 · B. Tombal, A. Choudhury, et al. · Annals of Oncology · 63

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

2022 · G. Gravis Mescam, X. Maldonado, et al. · Annals of Oncology · 17

Transcriptomics-Driven Machine Learning Models Accurately Predict Chemotherapy Response in Muscle-invasive Bladder Cancer

2024 · Ariadna Acedo-Terrades, Alejo Rodriguez-Vida, et al. · medRxiv · 1

Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey

2026 · Yuksel Urun, Kannan Sridharan, et al. · The Oncologist

2448P Organ-specific transcriptomic signatures in visceral metastases of metastatic hormone-sensitive prostate cancer

2025 · M. Garcia De Herreros, N. Jiménez Blasco, et al. · Annals of Oncology

2492P Impact of local treatment to the prostate in patients with de novo low-volume metastatic hormone-sensitive prostate cancer receiving androgen receptor pathway inhibitors

2025 · M. Wenzel, P. Mandel, et al. · Annals of Oncology

Works count: 6

Citation count: 81

H-index: 2

I10-index: 2